HTRF® cell-based phospho and total-HER3 assays for anti-cancer research
Overexpression of HER3, human epidermoid receptor 3/ ErbB3, is considered as an indicator for a poor prognosis in human breast cancer. Heterodimerization of HER3 with HER2 is associated with the increase in the aggressiveness of a breast cancer. HER3 is also been found to be involved in prostate, gastric, colon or other carcinomas. This makes HER3 a key target for anti-cancer therapies when screening or profiling small molecule TK inhibitors or biotherapeutic antibodies to induce ADCC and/or block HER3 heterodimerization.
Cisbio’s homogeneous and robust HTRF® phospho-HER3 (Tyr1289) assay kit is designed for the cell-based quantitative detection of HER3 signaling activity. The HTRF® total HER2 assay kit is designed for the quantitative detection of total HER3, phosphorylated and unphosphorylated, to normalize the phosphorylation status of HER3.
The buffers of both HTRF® phospho- and total HER3 assays are compatible, enabling an analysis of the phosphorylated and the total protein populations from one lysate sample.